Intersect ENT to Announce Third Quarter Financial Results

MENLO PARK, Calif., Oct. 21, 2014 (GLOBE NEWSWIRE) -- Intersect ENT, Inc. (Nasdaq:XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it will release its third quarter financial results on November 5, 2014. The Company expects to issue the release at approximately 4:00 p.m. EST and management will host a conference call at 4:30 p.m. EST that same day.

To access the conference call via the Internet, go to the "Investor Relations" page of the Company's web site at www.intersectENT.com. To access the live conference call via phone, dial 1-866-652-5200 and ask to join the Intersect ENT call. International callers may access the live call by dialing 1-412-317-6060. Participants may expedite telephone access by pre-registering for the call using the following link http://dpregister.com/10054909.

A replay of the conference call may be accessed that same day after 8:00 p.m. EST at www.intersectENT.com or via phone at 1-877-344-7529 or 1-412-317-0088 for international callers. The reference number to enter the replay of the call is 10054909. The dial-in replay will be available for a week after the call and via the Internet for approximately one month.

About Intersect ENT

Intersect ENT, Inc. is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The company markets two drug-eluting implants, PROPEL and PROPEL mini, clinically proven to improve surgical outcomes for patients with chronic sinusitis undergoing ethmoid sinus surgery. In addition, Intersect ENT is developing new drug-eluting implants designed to provide ENT physicians with even more customized options to treat patients with chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition leading to debilitating symptoms and chronic infections, and is one of the most costly conditions to U.S. employers.

CONTACT: Jeri Hilleman 650.641.2105 ir@intersectENT.com

Source:Intersect ENT

More From Press Releases